May 30, 2018

Symphogen further strengthens its immuno-oncology pipeline by advancing into two additional clinical trials

- Seventh program to enter clinical development at Symphogen.

- Symphogen’s antibody platform is now validated for immuno-oncology to deliver unique monoclonal antibody products.
Read more
November 30, 2017

Symphogen receives milestone payment for initiation of Phase 1b trial in infectious disease

Symphogen, a private clinical late-stage antibody oncology-focused company with a novel and differentiated antibody mixture pipeline, announced today that the company has received a $5 million milestone payment from Genentech, a member of the Roche Group, triggered by the initiation of a Phase 1b clinical trial evaluating DSTA4637S, an investigational medicine containing a Symphogen-generated antibody conjugated to an antibiotic agent for the potential treatment of Staphylococcus aureus (S.aureus) infections.
Read more
September 11, 2017

Symphogen presents detailed results for randomized Phase 2 study with Sym004 in refractory metastatic colorectal cancer at ESMO 2017 Congress

Symphogen, an advanced clinical-stage antibody company focused on oncology, today announced detailed results from its randomized Phase 2 study with Sym004, a synergistic mAb mixture targeting epidermal growth factor receptor (EGFR), compared to investigator-choice chemotherapy or best-supportive-care, in patients with advanced metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR monoclonal antibodies (mAbs).
Read more
Read more about our ownership